Prostamax is a synthetic tetrapeptide bioregulator developed by the St. Petersburg Institute of Bioregulation and Gerontology. It is designed to target prostate tissue and support normal prostate gland function. It belongs to the Khavinson peptide bioregulator class, which theorizes that short peptides can restore tissue-specific gene expression patterns that deteriorate with age.

Prostamax is proposed to interact with DNA in prostate epithelial cells, modulating the expression of genes involved in cell proliferation, apoptosis, and tissue homeostasis. Research suggests it may normalize the balance between cell growth and programmed cell death in prostate tissue, support healthy androgen receptor signaling, and promote antioxidant defenses within the prostate gland.

• Normalized prostate gland histological structure in aged rat models (Khavinson et al., 2009)
• Modulated expression of proliferation markers (Ki-67) in prostate tissue cultures
• Improved urodynamic parameters in aged animal models of benign prostatic changes
• Demonstrated anti-inflammatory effects in prostate tissue explants
• Showed gene-regulatory activity when applied to prostate cell nuclear extracts in vitro

1. Peptide bioregulation of aging: results and prospects
   Adv Gerontol, 2009
2. Short peptides and their role in regulation of prostate function
   Bull Exp Biol Med, 2010
3. Geroprotective effects of peptide bioregulators
   Rejuvenation Res, 2014

Available for Research

Lab-tested, third-party COA published, U.S. ships same day.